in

Astraveus Raises €16.5 Million Series Seed Round to Advance Automated Cell and Gene Therapy Manufacturing Platform

Astraveus Secures Funding to Revolutionize Cell and Gene Therapy Manufacturing

Key Takeaways:

  • Astraveus SAS, the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, has successfully raised €16.5 million in a Series Seed financing round. The funding, led by AdBio partners and co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture, will support Astraveus in advancing the development of its innovative technology and expanding its team.
  • Astraveus aims to revolutionize the field of CGT manufacturing with its Lakhesys™ platform, an end-to-end cell foundry that utilizes deep process optimization and single-use, microfluidic bioprocessors to improve efficiency and reduce costs. By eliminating the need for large-scale infrastructure and addressing logistical challenges, Astraveus seeks to enhance patient access to life-changing cell and gene therapies.
  • At the heart of Astraveus’ Lakhesys platform are microfluidic bioprocessors, which mimic organ perfusion and significantly accelerate molecular exchanges necessary for the transformation of cells into therapeutic agents. The precision and miniaturization enabled by microfluidic bioprocessors streamline manufacturing, reducing labor, floor space, and energy requirements. As a result, the process becomes more cost-effective and environmentally friendly, generating less waste.
  • The funding round saw participation from key investors who recognized Astraveus’ disruptive technology and potential to address significant unmet needs in CGT enabling technologies. Alain Huriez of AdBio partners, Christian Uhrich of M Ventures, Fiona MacLaughlin of JJDC Inc., and Laurent Higueret of Bpifrance Large Venture will join the Astraveus board.

Transforming Cell and Gene Therapy Manufacturing

Astraveus is committed to transforming cell and gene therapy manufacturing through its innovative Lakhesys platform. By optimizing processes and incorporating microfluidic bioprocessors, Astraveus aims to deliver better therapies in a more efficient, cost-effective, and environmentally sustainable manner. The Lakhesys platform’s modular scalability and reduced vein-to-vein times have the potential to revolutionize clinical research, accelerate the adoption of cell and gene therapies, and make these lifesaving treatments accessible to a wider patient population.

Jérémie Laurent, Founder and CEO of Astraveus, expressed his ambition to revolutionize the development and commercialization of cell and gene therapies. By reducing costs, increasing precision, and driving scalability, Astraveus aims to unlock the full potential of these therapies and expand their accessibility to a broader patient base.

Alain Huriez, Chairman and Managing Partner of AdBio partners, emphasized Astraveus’ disruptive technology and its potential to address unmet needs in CGT enabling technologies. The strong syndicate of co-investors recognized the company’s potential and invested to support Astraveus in becoming a leader in this vital field.

Christian Uhrich, Principal at M Ventures, praised Astraveus’ unique technology and approach, stating that it represents a step change in delivering access to life-changing therapies. Supported by a strong innovation ecosystem, Astraveus has already achieved remarkable milestones, and Uhrich is confident in the company’s ability to fully realize the technology’s potential.

Laurent Higueret, Senior Investment Director at Bpifrance Large Venture, expressed excitement about joining a syndicate of expert and long-term investors. Higueret believes that Astraveus’ cutting-edge CGT platform holds tremendous promise in reducing vein-to-vein times for patients requiring cell therapy products. This positions Astraveus as a key player in the field and aligns with Bpifrance’s mission to support disruptive technologies and entrepreneurial successes.

About Astraveus

Astraveus is developing the next generation of cell and gene therapy (CGT) manufacturing solutions. The company’s cell foundries leverage modular, microfluidic technologies to optimize the manufacturing process, delivering improved therapies more efficiently. Astraveus aims to enable a therapeutic revolution at scale by reducing costs, enhancing precision, and increasing scalability, thereby making cell and gene therapies accessible to thousands of patients worldwide. Founded in 2016 by Jérémie Laurent at the St Louis Hospital in Paris, Astraveus is a member of the #FrenchTech2030 program.

For more information, visit www.astraveus.com.

About AdBio partners

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated company specializing in investments within the life sciences sector, particularly in therapeutics-oriented projects. AdBio partners’ strategy combines early-stage investments with entrepreneurial support to foster company growth. With 22 European investments in France, Belgium, Spain, and Ireland, AdBio partners has attracted international venture capital syndicates to its portfolio companies. The team at AdBio partners comprises investment professionals with extensive experience in entrepreneurial ventures, along with scientific, medical, and operational expertise.

For more information, visit www.adbio.partners.

About M Ventures

M Ventures is the strategic corporate venture capital arm of Merck, investing globally in transformational ideas driven by innovative entrepreneurs. With headquarters in the Netherlands and offices in Germany, the United States, and Israel, M Ventures actively engages with its portfolio companies, collaborating with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on financing novel solutions to challenging problems in various fields, aiming to impact the vitality and sustainability of Merck’s current and future businesses.

For more information, visit www.m-ventures.com.

About Bpifrance and Bpifrance Large Venture Fund

Bpifrance, the French Public Investment Bank, offers a comprehensive range of financial products and services to domestic companies at every stage of their development. Its offerings include equity, loans, guarantees, export insurances, as well as consultancy and training.

Bpifrance’s Large Venture fund, with a size of €1.75 billion, focuses on fast-growing, highly innovative startups seeking to accelerate organic or external growth. Since its creation in 2013, the Large Venture fund has invested in more than 60 companies in the healthtech, life sciences, digital, and greentech sectors.

For more information, visit www.bpifrance.com

SuperScale Raises $5.4M Series A to Grow Revenue for Game Developers and Publishers

Brilliant Labs Raises US$3.0 Million in Seed Funding to Develop Generative AI-Embedded AR Glasses